Business Context and Reporting Period
This Form 8-K Current Report was filed by Supernus Pharmaceuticals, Inc. on August 1, 2024. The report addresses a specific corporate event regarding the company's drug development pipeline rather than a standard financial reporting period.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report on a specific event and does not contain financial statements or performance metrics.
Material Changes
The primary material event reported is the resubmission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA):
- Product: SPN-830 (apomorphine infusion device).
- Indication: Continuous treatment of motor fluctuations (OFF episodes) in Parkinson's disease.
- Action: Resubmission of the NDA on August 1, 2024.
Guidance, Outlook, and Risks
The filing contains forward-looking statements regarding the company's plans and strategies but explicitly states that the company undertakes no obligation to update these statements. The document references various risks and uncertainties, directing investors to the "Risk Factors" section of the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2023, for a comprehensive list of potential risks.
Investor Verification Checklist
- Verify the status of the resubmitted NDA for SPN-830 via FDA databases or subsequent press releases.
- Review the full text of the press release furnished as Exhibit 99.1 for additional details on the resubmission rationale.
- Consult the most recent Form 10-K or 10-Q for current financial health, cash runway, and debt obligations, as this 8-K does not contain such data.
- Monitor for any FDA responses or requests for additional information following the resubmission.